20/20 Biolabs, Inc. (AIDX)
NASDAQ: AIDX · Real-Time Price · USD
0.4220
+0.0130 (3.18%)
Sep 29, 2026, 1:49 PM EDT - Market open
20/20 Biolabs Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2.04 | 2.05 | 1.75 | 1.42 | 11.06 | 9.62 | |
Revenue Growth | 2.73% | 16.71% | 23.03% | -87.12% | 14.93% | 3373.18% |
Cost of Revenue | 1.4 | 1.44 | 1.39 | 1.32 | 5.94 | 4.93 |
Gross Profit | 0.64 | 0.6 | 0.36 | 0.11 | 5.12 | 4.69 |
Selling, General & Admin | 4.37 | 3.34 | 4.76 | 5.06 | 3.32 | 2.56 |
Research & Development | 0.67 | 0.59 | 1.26 | 1.41 | 0.12 | 0.19 |
Operating Expenses | 5.04 | 3.94 | 6.02 | 6.47 | 3.44 | 2.75 |
Operating Income | -4.4 | -3.33 | -5.66 | -6.36 | 1.68 | 1.94 |
Interest Expense | -0.69 | -0.16 | -0.01 | -0.03 | -0.02 | -0.01 |
Interest & Investment Income | 0.03 | 0.02 | 0.08 | 0.21 | 0.07 | 0 |
Other Non Operating Income (Expenses) | -0.75 | -0.27 | 0.06 | -0 | 0.45 | 0.14 |
EBT Excluding Unusual Items | -5.81 | -3.74 | -5.54 | -6.18 | 2.18 | 2.07 |
Gain (Loss) on Sale of Assets | - | - | - | - | 0 | - |
Asset Writedown | - | - | -0.02 | -0.21 | - | - |
Pretax Income | -5.81 | -3.74 | -5.55 | -6.39 | 2.19 | 2.07 |
Net Income | -5.81 | -3.74 | -5.55 | -6.39 | 2.19 | 2.07 |
Net Income to Common | -7.12 | -3.74 | -5.55 | -6.39 | 2.19 | 2.07 |
Net Income Growth | - | - | - | - | 5.56% | - |
Shares Outstanding (Basic) | 7 | 5 | 5 | 5 | 5 | 5 |
Shares Outstanding (Diluted) | 7 | 5 | 5 | 5 | 9 | 9 |
Shares Change | 47.91% | 2.70% | 0.66% | -49.73% | 0.26% | 100.78% |
EPS (Basic) | -1.00 | -0.76 | -1.16 | -1.34 | 0.46 | 0.44 |
EPS (Diluted) | -1.00 | -0.76 | -1.16 | -1.34 | 0.23 | 0.22 |
EPS Growth | - | - | - | - | 4.55% | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -2.79 | -1.92 | -2.6 | -4.49 | 5.54 | -1.3 |
Free Cash Flow Per Share | -0.39 | -0.39 | -0.54 | -0.94 | 0.58 | -0.14 |
Gross Margin | 31.52% | 29.56% | 20.56% | 7.66% | 46.31% | 48.79% |
Operating Margin | -215.70% | -162.87% | -323.06% | -446.64% | 15.18% | 20.18% |
Profit Margin | -348.74% | -182.82% | -316.81% | -448.73% | 19.77% | 21.53% |
Free Cash Flow Margin | -136.84% | -93.87% | -148.30% | -315.20% | 50.11% | -13.53% |
EBITDA | -4.32 | -3.25 | -5.52 | -6.2 | 1.9 | 2.07 |
EBITDA Margin | -211.83% | -158.68% | - | - | 17.18% | 21.47% |
D&A For EBITDA | 0.08 | 0.09 | 0.14 | 0.17 | 0.22 | 0.12 |
EBIT | -4.4 | -3.33 | -5.66 | -6.36 | 1.68 | 1.94 |
EBIT Margin | -215.69% | -162.87% | - | - | 15.18% | 20.18% |
Advertising Expenses | - | 0.17 | 0.53 | 0.78 | 0.36 | - |